The presence of HLA-B75, DR13 homozygosity or DR14 additionally increases the risk of allopurinol induced severe cutaneous adverse reactions in HLA-B*58:01 carriers

ConclusionSecondary screening with HLA-B75, DR13 homozygosity, and DR14 in addition to primary screening with HLA-B*58:01 would enable a more accurate prediction of SCAR occurrence, especially in patients with CRI. (Source: The Journal of Allergy and Clinical Immunology: In Practice)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2SDNYfD